Patient characteristics Intervention Comparison Length of followup
|
|
- Jasmine Waters
- 6 years ago
- Views:
Transcription
1 ORAL MUCOLYTICS Ref ID: 2511 Bachh AA, Shah NN, Bhargava R et al. Effect oral N- in COPD - A randomised controlled trial. JK Practitioner. 2007; 14(1): Ref ID: 2511 RCT Single blind; unclear allocation concealment; unclear method randomisation; unclear if ITT; loss to follow-up: not stated 1 centre- India N = 100 Patient characteristics Intervention Comparison Length Inclusion: people > 50 years old with smoking-related COPD who had 2 s COPD/year during previous 24 months; smokers and nonsmokers included; FEV 1 reversibility < 12% predicted value; an FEV 1 /FVC ratio < 0.70 and post FEV 1 between 30%-80% predicted value. Exclusion: history asthma; intolerance to ; who had taken for > 3 months previously; CHF class > 2; treatment with oral corticosteroids; Baseline characteristics: similar between groups N-acetyl cysteine (600 mg/once daily) for 4 months N= 50 for 4 months N=50 Procedure:. randomised to or placebo. Both arms permitted standard treatment for COPD according to GOLD guidelines; ICS allowed at a fixed dose throughout study Outcome measures 1 year Primary outcome: rate over 1 year ( defined increased dyspnoea and/or increased sputum purulence, volume, which leads the patient to seek medical attention and lasting 3 days) Secondary outcomes: Post FEV 1 % predicted Hospitalisations Not stated placebo Mean age (y) Mean post % predicted FEV monitored every 2 months. medications during study placebo medication: % SABA 48 40
2 Comparison group is placebo LABA inhaled anticholinergics ICS outcome N=50 N= 50 people with At least 1 (n) P<0.01 Hospitalisations (n)* P <0.05 Change from baseline in post FEV 1 % predicted (SE) 4.6 (1.8) 3.9 (1.6) P <0.05 *unable to include this in the Poole meta analysis as unable to calculate rate ratio. Ref ID: 2493 Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Systematic Reviews Systematic Review / meta analysis Searched the Cochrane Airways Group Specialised Register trials, derived from systematic searches CENTRAL, MEDLINE, EMBASE and CINAHL, and hand searching respiratory journals and meeting abstracts N= RCTs Patient characteristics Inclusion criteria: adults > 20 years age with chronic bronchitis as defined by ATS, GOLD, ERS, WHO or the British Medical Research Council (cough and sputum on most days during at least three consecutive months for more than two successive years). Included 4 studies Intervention Comparison Length Oral mucolytics: Carbosysteine or Erdosteine or N- () [Have ignored all other mucolytic studies that are included in the Cochrane] 6 months 3 years Outcome measures number acute s. number pts with no in the study period, hospitalisation, lung function (FEV 1 ) and adverse events Cochrane Collaboration
3 mucolytics in COPD. Exclusion: with asthma or cystic fibrosis Frequency No in study period Hospitalisation in study period FEV1 or % predicted FEV1 or PEFR at end study Death during study period Adverse effects Mucolytic vs. placebo N- vs. placebo Carbocysteine vs. placebo Erdosteine vs. placebo WMD: (95% CI: to - WMD: (95% CI: to -0.04) WMD: (95% CI: to - WMD: (95% CI: -0.1 to ) 10 studies, N= ) 0.00) 13 studies, N= studies, N= study, N= 124 RR: 1.46 (95% CI: ) 11 studies, N=2101 RR: 0.76 (95% CI: ) 2 studies, N=678 SMD: 0.18 (95% CI: ) 8 studies, N=1664 Overall: RR: 0.95 (95% CI: ) 3 studies, N=801 More than one year follow up: RR: 1.04 (95% CI: ) 1 study, N=523 6 months follow up: RR: 0.61 (95% CI: ) 2 studies, N=278 RR: 0.82 (95% CI: ) 8 studies, N=2340 RR: 1.51 (95% CI: ) 8 studies, N=1516 RR: 1.30 (95% CI: ) 2 studies, N= SMD: 0.04 (95% CI: ) 6 studies, N=1431 SMD: 0.17 (95% CI: ) 1 study, N= RR: 0.86 (95% CI: ) 5 studies, N=1666 RR: 0.72 (95% CI: ) 2 studies, N=550 RR: 1.94 (95% CI: ) 1 study, N=124 SMD: 1.09 (95% CI: ) 1 study studies, N=124 RR: 0.71 (95% CI: ) 1 study, N=124 Included studies in meta-analysis Included trials Borgia 1981 Grassi 1976 Grillage 1985 Comparison Follow up N FEV1 Country Inclusion Criteria Drop outs Patient Characteristics 200mg vs placebo 6 months 21 >40 Italy 600mg vs. placebo 6 months 80 - Italy Carbosysteine 750mg vs. 6 months UK Chronic bronchitis defined by MRC and an in the period before the study 2 (10%) Mean age 45.3 years, FEV1 3.82L Chronic bronchitis defined by British and American criteria 11 (14%) Mean age 60.9, 80% male Chronic bronchitis defined by MRC. Reversibility <20% 11 (10%) Pts all over 40 years
4 placebo Rasmussen 1988 Moretti 2004 Pela 1999 Allegra 1996 Meister 1986 Boman 1983 Nowak 1999 Decramer 2005 Parr mg vs. placebo 6 months Sweden Erdosteine 300mg vs. placebo 8 months 155 <70 Italy 600mg vs. placebo 6 months 169 <70 Italy Carbocysteine 2.7g vs. placebo 6 months Italy 300mg vs. placebo 6 months Germany 200mg vs placebo 6 months 259 <50 Sweden Chronic bronchitis defined by MRC. 56 (22%) 600mg vs. placebo 8 months (mean) mg vs. placebo 3 years Europe 200mg vs. placebo 6 months UK Chronic bronchitis defined by MRC and at least one in previous winter 25 (22%) Mean age 58.9yrs, 57% male, 100% had smoked Mean age 67 yrs, 80% male, 33% smokers, FEV1 after salbutamol 1.68L (SD 0.31) in COPD defined by ERS age with one erdosteine grp and 1.59L in or more in previous winter 31 (20%) placebo grp Mean age 66, 76% male, 28% COPD defined by ATS and ERS aged current smokers, mean FEV1 reversibility <12% 6 (4%) 1.49L, 58% predicted 75% smoking history, mean 2.7 COPD (ATS defined) and chronic bronchitis. (SD 1.3) s in At least one in previous 12 previous year, FEV L (SD months. Age (16%) 0.6) ICS not permitted Chronic bronchitis defined by WHO with at Mean age 57.2 yrs, 59% male, least one in the last winter 71 (28%) 88% had smoked 100% smokers mean age 51.9 FEV1 80% predicted 60 (mean) Europe COPD 18 (6%) Mean age 57 yrs, 60% male COPD, reversibility <12% and 200ml, Mean age 62 (SD 8), 79% FEV1/FVC 88% for men and 89% women 70 (27%) in male, FEV1 1.65L (SD 0.38), and history at least 2 s in last group and 99 46% current smokers, 70% on 2 yrs (37%) in placebo ICS Chronic bronchitis defined by MRC with at least one in last 12 mths 204 (39%) Mean age 63, 66% male, 86% had smoked Babolini mg vs placebo 6 months Italy Chronic bronchitis defined by MRC. 249 (33%) 64.3% smokers, 73.5% male, mean FEV L Ref ID: 35 Schermer T, Chavannes N, Dekhuijzen R et al. RCT Randomised; double blind; N = 192 Patient characteristics Intervention Comparison Length Inclusion: people years old; current/former smoker; chronic dyspnoea, sputum production and cough for at N- (600 mg/once daily) N=96 Procedure: 3 Outcome measures 3 years Primary outcome: rate over 1 year ( Dutch Council for Health Insurances;
5 Fluticasone and N- in primary care with COPD or chronic bronchitis. Respiratory Medicine. 2009; 103(4): Ref ID: 35 allocation concealment; ITT; Drop outs: : 44/96 (45.8%) placebo: 40/96 (41.7%) multicentre- Netherlands least 3 consecutive months/year in previous 2 years; FEV 1 /FVC ratio < 88% (men) or < 89% (women) and post FEV 1 <90% Exclusion: post FEV 1 <40% and/or history asthma; allergic rhinitis, or allergic eczema Baseline characteristics: similar between groups placebo Mean age (y) Mean post % predicted FEV1 Mean yearly rate N= 96 month washout from and/or ICS. Two week pretreatment with 30 mg oral prednisolone o.d. randomised to or placebo. monitored every 3 months. defined increased dyspnoea and/or increased sputum purulence, volume, which leads the patient to seek medical attention. Moderate defined as requiring antibiotics or prednisolone. Severe defined as requiring ER visit or hospitalisation. Secondary outcomes: Change in post FEV 1 Netherlands Asthma Foundation medications during study placebo medication: % SABA LABA ICS death
6 Comparison group is placebo outcome N=96 N= 96 Mean number s/year (includes hospitalisation) 1.00 (95% CI 0.77, 0.73 (95% CI 0.57, Rate ratio 1.35; p= ) 0.88) Change from baseline in post BD-FEV1 at 3 years (adjusted for age, gender, - 64 ml (SE 5.4) -60 ml (SE 5.4) P=0.569 smoking, FEV1) Death 1 3 RR 0.33 (95% CI 0.04, 3.15) Ref ID: 2504 Zheng JP, Kang J, Huang SG et al. Effect on acute chronic obstructive pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet. 2008; 371(9629): Ref ID: 2504 RCT (PEACE) Double blinded; allocation concealment; ITT; powering the study not possible loss to follow-up: 13% 12% placebo Multicentre- China Patient characteristics Intervention Comparison Length N = 707 Inclusion: people between 40 and 80 years old with COPD who had 2 s COPD within previous 24 months and clinically stable for 4 weeks prior to study; smokers and non-smokers included; an FEV 1 /FVC ratio < 0.70 and post FEV 1 between 25%-79% predicted value. Exclusion: history asthma; non-copd respiratory disorder; previous lung transplantation or lung volume reduction surgery, requirement for LTOT or pulmonary rehab; alcohol/drug misuse; hypersensitivity to study medication; current use oral corticosteroids; onset during run-in period; severe glaucoma, heart, liver, kidney disease, diffuse bilateral bronchiectasis; (2x250 mg/3 times daily) N= 353 (2 tablets/3 times daily) N=354 Procedure:. randomised to or placebo. monitored every 3 months for 1 year. Both arms permitted short or long acting s and ICS if they had been used prior to study and the drugs were sustained Outcome measures 1 year Primary outcome: rate over 1 year ( defined as 2 day persistence at least 2 major symptoms worsening dyspnoea and increased sputum purulence, volume, or both; or any single major symptom plus more than 1 minor symptom such as wheezing, upper airway infection, unexplained fever) Secondary outcomes: Kyorin Pharma, Japan
7 Comparison group is placebo RR adjusted for concomitant use ICS outcome pregnancy or breastfeeding Baseline characteristics: similar between groups carbocystein e placebo Mean age (y) % beta agonists % anticholinergics % ICS Mean post FEV1 (L) Mean % predicted FEV1 Mean SRGQ N=353 N= 354 during the study. Systemic corticosteroids, antibiotics, mucolytics, antitussives not permitted unless used to treat an during the study. Change in SGRQ Change in mean FEV 1 Adverse events Mean s/patient-year (SE) 1.01 (0.06) 1.35 (0.06) Adjusted rate ratio 0.75 (0.62, 0.92), p=0.004 Change in SGRQ (at 1 year) (SD) (16.43) (19.01) P = Change in mean pre FEV1 (at 1 year, litres) Data not shown Data not shown Authors state NS between the groups; but data not shown All-cause mortality at 1 year (n) 0 0 Not reported Adverse events (n) Not reported Note: low use ICS; beta 2 agonists, or anticholinergics in each arm; specific to a Chinese population.
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationThis is the publisher s version. This version is defined in the NISO recommended practice RP
Journal Article Version This is the publisher s version. This version is defined in the NISO recommended practice RP-8-2008 http://www.niso.org/publications/rp/ Suggested Reference Chong, J., Karner, C.,
More informationD DAVID PUBLISHING. 1. Introduction
Journal of Health Science 2 (2014) 591-598 doi: 10.17265/2328-7136/2014.12.004 D DAVID PUBLISHING Comparative Efficacy and Safety of Two Formulations of Ipratropium Bromide (IB) HFA pmdi in Patients with
More informationDr Stephen Child. General Physician Auckland. 14:20-14:40 Secondary Care Perspective
Dr Stephen Child General Physician Auckland 14:20-14:40 Secondary Care Perspective Wheeze Witchery Stephen Child MD, FRACP, FRCPC General Physician Respiratory Interest Director of Clinical Training Auckland
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 May 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 May 2011 Examination of the file for the proprietary medicinal product included for a period of 5 years by the
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationAirway Vista Background
Airway Vista 2013 Chronic Obstructive Airway Diseases Symposium Asan Medical Center, Seoul, South Korea When Should Macrolide Antibiotics be Prescribed to Prevent COPD Exacerbations in Usual Clinical Practice?
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationAsthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research
Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What
More informationUpdate on heterogeneity of COPD, evaluation of COPD severity and exacerbation
Update on heterogeneity of COPD, evaluation of COPD severity and exacerbation Yung-Yang Liu, MD Taipei Veterans General Hospital Aug 29, 2015 G O lobal Initiative for Chronic bstructive L D ung isease
More informationCombination inhaled steroid and long-acting beta -agonist in
Combination inhaled steroid and long-acting beta 2 -agonist in addition to tiotropium versus tiotropium or combination alone for chronic Karner C, Cates CJ This is a reprint of a Cochrane review, prepared
More informationInhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)
Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Spencer S, Evans DJ, Karner C, Cates CJ This is a reprint of a Cochrane review, prepared and
More informationWhat is COPD? COPD Pharmacotherapy. COPD Mortality Is Increasing
COPD Pharmacotherapy Chronic Bronchitis What is COPD? 75% 17.5% Emphysema Laura C. Feemster, MD, MS Assistant Professor University of Washington Division of Pulmonary & Critical Care April 23,2015 COPD
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of insertion of endobronchial nitinol coils to improve lung function in emphysema
More informationInfluence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
REVIEW N-ACETYLCYSTEINE AND COPD EXACERBATIONS Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis Mario Cazzola 1, Luigino Calzetta 1, Clive Page 2, Josè Jardim
More informationModel based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking
Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRole of mucolytics in the management of COPD
REVIEW Role of mucolytics in the management of COPD Phillippa J Poole University of Auckland, Auckland, New Zealand Abstract: There is, to date, no medical therapy that modifies the decline in lung function
More informationCurrent Approaches to Asthma & COPD
10/11/18 Current Approaches to Asthma & COPD Lekshmi Santhosh, M.D. Assistant Professor, Pulm/Critical Care & Hosp Med Primary Care Medicine: Principles & Practice 10.11.2018 Revisiting the Dutch Hypothesis:
More informationCOPD/ Asthma. Dr Heather Lewis Honorary Clinical Lecturer
COPD/ Asthma Dr Heather Lewis Honorary Clinical Lecturer Objectives To understand the pathogenesis of asthma/ COPD To recognise the clinical features of asthma/ COPD To know how to diagnose asthma/ COPD
More informationInhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review)
Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Spencer S, Karner C, Cates CJ, Evans DJ This is a reprint of a Cochrane review, prepared and
More informationSurgery versus non-surgical treatment for bronchiectasis (Review)
Surgery versus non-surgical treatment for bronchiectasis (Review) Warburton CJ, Corless JA This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in
More informationExacerbations of COPD. Dr J Cullen
Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationCOPD in Korea. Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum
COPD in Korea Division of Pulmonary, Allergy and Critical Care Medicine of Hallym University Medical Center Park Yong Bum Mortality Rate 1970-2002, USA JAMA,2005 Global Burden of Disease: COPD WHO & World
More informationChronic Obstructive Pulmonary Disease (COPD).
Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationKirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo,
Kirthi Gunasekera MD Respiratory Physician National Hospital of Sri Lanka Colombo, BRONCHODILATORS: Beta Adrenoreceptor Agonists Actions Adrenoreceptor agonists have many of the same actions as epinephrine/adrenaline,
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationAECOPD: Management and Prevention
Neil MacIntyre MD Duke University Medical Center Durham NC Professor P.J. Barnes, MD, National Heart and Lung Institute, London UK Professor Peter J. Barnes, MD National Heart and Lung Institute, London
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationNebulised hypertonic saline for cystic fibrosis.
Revista: Cochrane Database Syst Rev. 2003;(1):CD001506. Nebulised hypertonic saline for cystic fibrosis. Autor: Wark PA, McDonald V. Source: Department of Respiratory Medicine, John Hunter Hospital, Locked
More informationInhaled corticosteroids (ICS) such as fluticasone
Eur Respir J 2010; 35: 1003 1021 DOI: 10.1183/09031936.00095909 CopyrightßERS Journals Ltd 2010 Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD Y.K.
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationReferring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL
Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More information62 year old man with a cough! Dr. Aflah Sadikeen Consultant Respiratory Physician Colombo
62 year old man with a cough! Dr. Aflah Sadikeen Consultant Respiratory Physician Colombo History Mr.KS, a 62 year-old, has been feeling unwell - Worsening cough for the last 5 days - Feels out of breath
More informationInfluenza vaccine for patients with chronic obstructive pulmonary disease (Review)
Influenza vaccine for patients with chronic obstructive pulmonary disease (Review) Poole P, Chacko EE, Wood-Baker R, Cates CJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationDrug Class Review on Beta 2 -Agonists
Drug Class Review on Beta 2 -Agonists Final Report s November 2006 The Agency for Healthcare Research and Quality has not seen or apporved this report A literature scan of this topic is done periodically.
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationChronic Obstructive Pulmonary Disease
Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the
More informationCopyright General Practice Airways Group. Reproduction Prohibited
Primary Care Respiratory Journal (2004) 13, 84 88 REVIEW The NICE COPD Guidelines 2004 what are the messages for primary care? David Bellamy*,1 James Fisher Medical Centre, 4 Tolpuddle Gardens, Muscliffe,
More informationAntibiotic Therapy in Preventing Exacerbations of Severe Chronic Obstructive Pulmonary Disease
University of North Dakota UND Scholarly Commons Physician Assistant Scholarly Project Papers Department of Physician Studies 2018 Antibiotic Therapy in Preventing Exacerbations of Severe Chronic Obstructive
More informationTreatment Responses. Ronald Dahl, Aarhus University Hospital, Denmark
Asthma and COPD: Are They a Spectrum Treatment Responses Ronald Dahl, Aarhus University Hospital, Denmark Pharmacological Treatments Bronchodilators Inhaled short-acting β -Agonist (rescue) Inhaled short-acting
More informationEffect of N-Acetylcysteine on Air Trapping in COPD. A Randomized Placebo-Controlled Study
CHEST Effect of N-Acetylcysteine on Air Trapping in COPD A Randomized Placebo-Controlled Study David Stav, MD; and Meir Raz, MD Original Research COPD Background: FEV 1 is used for the classification of
More informationHQO s Episode of Care for Chronic Obstructive Pulmonary Disease
HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationChronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease 07 Contributor Dr David Tan Hsien Yung Definition, Diagnosis and Risk Factors for (COPD) Differential Diagnoses Goals of Management Management of COPD THERAPY AT EACH
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2017?
Global Initiative for Asthma (GINA) GINA Global Strategy for Asthma Management and Prevention Asthma-COPD overlap The word syndrome has been removed from the previous term asthma-copd overlap syndrome
More informationMedicines Management of Chronic Obstructive Pulmonary Disorder (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disorder (COPD) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (NHS Wandsworth) and Reena Rabheru-Dodhy (NHS Sutton & Merton) Date Prepared:
More informationConsultation Toolkit
Chronic Obstructive Pulmonary Disease (COPD) Consultation Toolkit Introduction Chronic obstructive pulmonary disease (COPD) is currently the fifth leading cause of death and is set to become the third
More informationSelf-management education for patients with chronic obstructive pulmonary disease (Review)
Self-management education for patients with chronic obstructive pulmonary disease (Review) Effing T, Monninkhof EEM, van der Valk PP, Zielhuis GGA, Walters EH, van der Palen JJ, Zwerink M This is a reprint
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 www.nice.org.uk/ta244 NHS Evidence has accredited the process used by the Centre for Health Technology
More informationYou ve come a long way, baby.
COPD Dr Badri Paudel Dept of Medicine GMC/CHRC 4/22/12 badri@gmc 2 You ve come a long way, baby. Wayne McLaren Former Marlboro Man 4/22/12 badri@gmc 3 Age 30 a robust young man Age 51 riding into the sunset
More informationAsthma Tutorial. Trainer MRW. Consider the two scenarios, make an attempt at the questions, what guidance have you used?
Registrar: LG PR RS Topic Asthma and COPD Asthma Tutorial Trainer MRW Date of Tutorial 18 th Jan 2007 Objectives of the tutorial How to diagnose What investigations and when Treatment guidelines QoF Criteria
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRoflumilast for the management of severe chronic obstructive pulmonary disease
Roflumilast for the management of severe chronic obstructive pulmonary disease Issued: January 2012 guidance.nice.org.uk/ta244 NICE has accredited the process used by the Centre for Health Technology Evaluation
More informationC hronic obstructive pulmonary disease (COPD) is one of
589 RESPIRATORY INFECTIONS Time course of recovery of health status following an infective exacerbation of chronic bronchitis S Spencer, P W Jones for the GLOBE Study Group... Thorax 2003;58:589 593 See
More informationChronic obstructive pulmonary disease
Behind the Medical Headlines Chronic obstructive pulmonary disease 2007 Royal College of Physicians of Edinburgh 1 P Albert, 2 P Calverley 1 Clinical Research Fellow, 2 Professor of Respiratory and Rehabilitation
More informationChronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC
Chronic Obstructive Pulmonary Disease (COPD) KAREN ALLEN MD PULMONARY & CRITICAL CARE MEDICINE VA HOSPITAL OKC / OUHSC I have no financial disclosures Definition COPD is a preventable and treatable disease
More informationQuestion by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD)
Question by Question (QXQ) Instructions for the Pulmonary Diagnosis Form (PLD) A Pulmonary Diagnosis Form is filled out by the reviewer for all medical records that are sent to them for review by the CSCC.
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationProphylactic antibiotic therapy for chronic obstructive pulmonary disease(copd)(review)
Cochrane Database of Systematic Reviews Prophylactic antibiotic therapy for chronic obstructive pulmonary disease(copd)(review) HerathSC,PooleP Herath SC, Poole P. Prophylactic antibiotic therapy for chronic
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationDecline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO)
Version V1.4 Decline In lung-function Among Patients with chronic obstructive Lung disease On maintenance therapy (DIAPLO) An observational study evaluating the benefits of early intervention with maintenance
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 6, Issue 12 Newsletter Date: December 2014 APSR EDUCATION PUBLICATION Inside this issue: COPD Simvastatin for the prevention of exacerbations in moderate-to severe COPD
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationNON-CF BRONCHIECTASIS IN ADULTS
Séminaire de Pathologie Infectieuse Jeudi 25 juin 2008 Cliniques Universitaires UCL de Mont-Godinne, Yvoir NON-CF BRONCHIECTASIS IN ADULTS Dr Robert Wilson Royal Brompton Hospital, London, UK Aetiology
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationJournal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More information